Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types—Hepatitis A, B, ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Researchers in India evaluated 1387 adults with asymptomatic hepatitis B virus (HBV) infection to determine the correlation between liver-enzyme elevations and histologic disease. Presumably ...

Objective Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, contributing to the production of hepatitis B surface antigen (HBsAg) and to hepatocarcinogenesis. In this ...